LT-626

CAT: 0804-HY-148302Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-148302Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
LT-626 is a potent PARP inhibitor with an IC50 of 1.60 nM. LT-626 inhibits cellular PAR synthesis with an EC50 of 17.9 nM and shows enhanced cytotoxicity in colorectal cancer cells harboring MRE11 mutations. LT-626 exhibits synergistic effects with Cisplatin (HY-17394), Oxaliplatin (HY-17371), and SN-38 (HY-13704) in colorectal cancer cells. LT-626 can be used for colorectal research[1].
CAS Number
[1207456-03-8]
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
PARP
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Field of Research
Cancer
Smiles
CN1C([C@H]2C=3C4=C(N[C@@H]2C5=CC=C(F)C=C5)C=C(F)C=C4C(=O)NN3)=NC=C1
Molecular Formula
C20H15F2N5O
Molecular Weight
379.37
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]McPherson LA, et al. Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells. Cancer Lett. 2014 Feb 28;343 (2) :217-23.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products